Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Radiation Injuries 3Pancreatic Neoplasms 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Vulvar Neoplasms 1Thymoma 1Thymic epithelial tumor 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Rare Diseases 1Pancreatic Cancer Non-resectable 1Ovarian Neoplasms 1Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 23venetoclax 17Dexamethasone 16pembrolizumab 15fludarabine 15Cytarabine 13pomalidomide 8Rituximab 8Gemcitabine 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7selinexor 6Paclitaxel 6Injections 6Immunotherapy, Adoptive 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Oxaliplatin 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Heavy Ion Radiotherapy × Clear all
NCT05457595 2025-08-06

CYCLOPS

CNAO National Center of Oncological Hadrontherapy

Phase NA Recruiting
55 enrolled
Gynecologic

Carcinoma, Ovarian Neoplasms, Recurrence, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡